Thiotepa and Azacitidine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Thiotepa (thiotepa) and Azacitidine (azacitidine). Common drug interactions include nausea among females and blood bilirubin decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Thiotepa and Azacitidine. It is created by eHealthMe based on reports of 75 people who take the same drugs from the FDA, and is updated regularly.

What is Thiotepa?

Thiotepa has active ingredients of thiotepa. eHealthMe is studying from 8,097 Thiotepa users. Check the latest studies of Thiotepa.

What is Azacitidine?

Azacitidine has active ingredients of azacitidine. eHealthMe is studying from 17,184 Azacitidine users. Check the latest studies of Azacitidine.

On Jul, 19, 2026

75 people who take Thiotepa and Azacitidine together, and have interactions are studied.

Thiotepa and Azacitidine drug interactions.

What are the common drug interactions of Thiotepa and Azacitidine, by gender? *:

female:

Nausea (feeling of having an urge to vomit)
Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Cardiac failure
Cardiomyopathy (weakening of the heart muscle)
Ejection fraction decreased (systolic heart failure)
Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Oedema peripheral (superficial swelling)
Drug ineffective
Graft versus host disease in skin (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the skin)
Calculus urinary (stone in urinary system)

male:

Blood bilirubin decreased
Hepatic failure (liver failure)
Bone marrow failure
Basal cell carcinoma (a skin cancer, it rarely metastasizes or kills)
Deafness
Odontogenic cyst (a group of jaw cysts that are formed from tissues of teeth development)
Second primary malignancy (after getting cure a cancer, a new cancer development)
Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Ascites (accumulation of fluid in the abdominal cavity)
Cytogenetic abnormality

What are the common drug interactions of Thiotepa and Azacitidine, by age (0-1 to 60+)? *:

0-1:

Drug ineffective
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Disease progression

2-9:

Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
Hepatitis (inflammation of the liver)
Fungaemia (fungi circulate in the blood)
Hepatic failure (liver failure)
Nausea (feeling of having an urge to vomit)
Abdominal distension
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Hepatomegaly (abnormal enlargement of the liver)
Malignant neoplasm progression (cancer tumour came back)
Venoocclusive disease (small veins in the liver are obstructed)

10-19:

Drug ineffective
Nausea (feeling of having an urge to vomit)
Vomiting
Deafness
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Osteosarcoma (a cancerous (malignant) bone tumour)
Disease progression
Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Bone marrow failure
Cytogenetic abnormality

20-29:

Blood bilirubin decreased
Venoocclusive disease (small veins in the liver are obstructed)
Aplasia (defective development or congenital absence of an organ or tissue)
Drug ineffective
Hepatic failure (liver failure)
Renal failure (kidney dysfunction)
Respiratory failure (inadequate gas exchange by the respiratory system)
Venoocclusive liver disease (small veins in the liver are obstructed)
Bone marrow failure
Graft versus host disease in skin (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the skin)

30-39:

Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
Blood bilirubin increased
Rectal haemorrhage (bleeding from anus)
Shock haemorrhagic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to excess bleeding)
Staphylococcal bacteraemia (a bacterial infection of blood)
Venoocclusive liver disease (small veins in the liver are obstructed)

40-49:

Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Oedema peripheral (superficial swelling)
Calculus urinary (stone in urinary system)
Diarrhoea
Febrile neutropenia (fever with reduced white blood cells)
Graft versus host disease in skin (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the skin)
Nausea (feeling of having an urge to vomit)
Pyrexia (fever)
Encephalitis viral (inflammation of the brain due to viral infection)

50-59:

Pulmonary veno-occlusive disease (obstructive disease of the pulmonary veins)
Acute graft versus host disease in liver (acute complication in liver following an allogeneic tissue/blood transplant)
Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
Pulmonary hypertension (increase in blood pressure in the lung artery)
Chronic graft versus host disease in skin (damage by immune cells to skin after grafting)
Headache (pain in head)
Hypersensitivity
Neutropenia (an abnormally low number of neutrophils)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Rash maculo-papular (red area on the skin that is covered with small confluent bumps)

60+:

Cardiac failure
Cardiomyopathy (weakening of the heart muscle)
Epstein-barr virus infection
Pleural effusion (water on the lungs)
Respiratory failure (inadequate gas exchange by the respiratory system)
Ejection fraction decreased (systolic heart failure)
Ascites (accumulation of fluid in the abdominal cavity)
Hepatic failure (liver failure)
Pericardial effusion (fluid around the heart)
Hepatotoxicity (chemical-driven liver damage)

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 39 people, 52.00%
Bone Marrow Conditioning Regimen: 30 people, 40.00%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 18 people, 24.00%
Nausea (feeling of having an urge to vomit): 12 people, 16.00%
Febrile Neutropenia (fever with reduced white blood cells): 12 people, 16.00%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 9 people, 12.00%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 8 people, 10.67%
Medulloblastoma (a fast-growing, high-grade tumour that always begins in the cerebellum): 4 people, 5.33%

* Approximation only. Some reports may have incomplete information.

Do you take Thiotepa and Azacitidine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously